OpenArc Corporate Advisory’s Cytokinetics CYTK Stock Holding History

OpenArc Corporate Advisory’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Buy	+2,792	New	+$200K	﹤0.01%	697

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OpenArc Corporate Advisory's CYTK Position: Q2 2026 in Review

OpenArc Corporate Advisory opened a new position in Cytokinetics (CYTK) in Q2 2026: 2,792 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #697 among its holdings.

480 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

OpenArc Corporate Advisory held 2,792 shares of Cytokinetics worth $238K as of Q2 2026.
Cytokinetics was a new OpenArc Corporate Advisory position in Q2 2026.
Cytokinetics made up ﹤0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #697 holding.
480 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.